This type of patient failed to benefit from any single immunotherapy, but microsatellite instability-high (pMMR-MSI-H) CRC responds well to immunotherapy because it can recruit a large number of immune cells such as CD8+/CD4+ T cells and macrophages into the microenvironment (39–42). This evidence concerns the gene CD4 and colorectal carcinoma.